SCHEDULE: FMR LLC Discloses 10.7% Stake in Amylyx Pharma
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have reported a 10.7% beneficial ownership stake in Amylyx Pharmaceuticals Inc., totaling 11,379,207 common shares.
Summary
- FMR LLC and Abigail P. Johnson beneficially own 11,379,207 shares of Amylyx Pharmaceuticals Inc. common stock.
- This ownership represents 10.7% of the company's outstanding common stock.
- The event requiring this Schedule 13G filing occurred on September 30, 2025.
- FMR LLC holds sole voting power over 11,361,910 shares and sole dispositive power over 11,379,207 shares.
- Abigail P. Johnson holds sole dispositive power over 11,379,207 shares.
- The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of the issuer.
- FMR LLC is classified as a parent holding company or control person.
- Fidelity Management & Research Company LLC, a subsidiary of FMR LLC, is identified as beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 7
Explanation: The disclosure of a significant institutional stake by a major asset manager like FMR LLC is generally viewed positively by the market, indicating confidence in the company's long-term prospects, even if the investment is passive.
Positives
- A significant institutional investment from FMR LLC, a major asset manager, signals confidence in Amylyx Pharmaceuticals Inc.'s long-term prospects.
- The acquisition of shares was stated to be in the ordinary course of business, indicating a passive investment rather than an activist stance, which can provide stability.
Risks
- This filing does not detail company-specific operational or financial risks for Amylyx Pharmaceuticals Inc.
- The investment by FMR LLC is passive and not intended to influence control, meaning FMR LLC will not actively drive strategic changes or management decisions.
Future Outlook
This filing does not contain specific forward-looking statements or guidance regarding Amylyx Pharmaceuticals Inc.'s future performance or strategic direction.
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
Industry Context
The increased stake by a prominent institutional investor like FMR LLC in a pharmaceutical company like Amylyx Pharmaceuticals Inc. suggests continued institutional interest in the biotechnology and pharmaceutical sectors, particularly in companies with potential for growth or significant product pipelines. Such investments often reflect a long-term view on the company's market position and future prospects.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure Disclosure | Abigail P. Johnson, as Director, Chairman, and CEO of FMR LLC, along with other Johnson family members, are predominant owners of Series B voting common shares (49% voting power) and have a shareholders' voting agreement, forming a controlling group with respect to FMR LLC. | NA | Clarifies the control structure of the reporting entity, FMR LLC, which is relevant for understanding the ultimate decision-makers behind the investment. |
Stakeholder Impact
- Shareholders: May view the significant institutional investment as a positive signal, potentially increasing confidence and attracting further investment.
- Management: Could interpret the investment as validation of their strategy and operations.
Next Steps
- This filing does not outline any specific future actions, events, or milestones for Amylyx Pharmaceuticals Inc. or the reporting persons beyond the ongoing passive investment.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number -23-000003) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number -23-000038) for Abigail P. Johnson was incorporated by reference. |
| 2025-09-30 | Date of event which required the filing of this statement. |
| 2025-10-06 | Date of signing of the Schedule 13G agreement. |
Recommendation
holdThe disclosure of a substantial 10.7% stake by a major institutional investor like FMR LLC is generally a positive signal, indicating confidence in Amylyx Pharmaceuticals Inc.'s long-term value. However, as this is a passive investment (filed under 13G, not 13D), it does not suggest an activist role or immediate strategic changes. For existing investors, this reinforces a 'hold' position, while new investors might consider it a favorable indicator for further due diligence.
Keywords
Amylyx Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.